Evidence map›Paper›PMID 39912938›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2025

Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer.

Xin Zhou, Shi Yan, Xiaopan Ma, Hua Zhu, Bing Liu, Xin Yang, Bing Jia, Zhi Yang, Nan Wu, Nan Li

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05156515 (PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05156515 naunknown statusnot on this map

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

TypeinterventionalSponsorPeking University Cancer Hospital & InstituteRan2021 to 2024Enrolled20ConditionsLung Cancer, Melanoma, PD-L1, PET/CTArms68Ga-THP-APN09
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. EfficientInternational journal of molecular sciences · 2026
    Article
  4. A high-affinity CEA-targeted nanobody forJournal of nanobiotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin ZhouState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Shi YanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Xiaopan MaState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Hua ZhuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Bing LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
Xin YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Bing JiaMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, No.38 Xueyuan Rd, Beijing, 100191, China. jiabing@bjmu.edu.cn.
Zhi YangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China. pekyz@163.com.
Nan WuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Beijing, 100142, China. nanwu@bjmu.edu.cn.
Nan LiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China. rainbow6283@sina.com.ORCID 0000-0001-8619-7550

Funding

Beijing Hospitals Authority's Ascent Plan DFL20241103Beijing Natural Science Foundation L222020, L248048Beijing Research Ward Excellence Program BRWEP2024W032150102Capital's Funds for Health Improvement and Research 2024-1-1023, 2022-02-1023Capital's Funds for Health Improvement and Research 2024-2-2153Capital's Funds for Health Improvement and Research No. 2022-2Z-2155National Key Research and Development Program 2022YFC2409405National Natural Science Foundation of China 82303583National Natural Science Foundation of China 82373082National Natural Science Foundation of China 82402318National Natural Science Foundation of China 82472015National Ten-thousand Talent Program National Ten-thousand Talent ProgramScience Foundation of Peking University Cancer Hospital 2022-05, 2022-11Science Foundation of Peking University Cancer Hospital PY202311
6 · The paper itself

Abstract

backgroundThis study aimed to assess the predictive and evaluative value of PD-L1 targeted

methodsFifty patients with resectable NSCLC enrolled in this prospective study underwent baseline

resultsThe SUV

conclusionBaseline

trial registrationNCT05156515, registered 8 December 2021, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000BMSI%26;selectaction=Edit%26;uid=U000503E%26;ts=2%26;cx=zeghuw .

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsAdultAgedFemaleGallium RadioisotopesHumansIsotope LabelingMaleMiddle AgedPositron Emission Tomography Computed TomographyTreatment OutcomeB7-H1 AntigenCD274 protein, humanGallium Radioisotopes68Ga-THP-APN09Neoadjuvant immunotherapyPET/CTResectable NSCLCToripalimab

Identifiers

PMID39912938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.